Mark W. Frohlich

May 31, 2024 | bioprocessintl.com | Diane McCarthy |Brian Gazaille |Tim Moore |Mark W. Frohlich

Allogeneic cell therapy has become an entrenched concept in the biopharmaceutical industry. Despite clear successes for autologous therapies, especially those based on chimeric antigen receptor (CAR) T cells, cell-therapy companies have yet to devise scalable means for making drug products based on cellular material from and for individual patients. Thus, many cancer patients are left without access to potentially life-saving treatment.

May 31, 2024 | bioprocessintl.com | Diane McCarthy |Brian Gazaille |Mark W. Frohlich |Tim Moore

Allogeneic cell therapy has become an entrenched concept in the biopharmaceutical industry. Despite clear successes for autologous therapies, especially those based on chimeric antigen receptor (CAR) T cells, cell-therapy companies have yet to devise scalable means for making drug products based on cellular material from and for individual patients. Thus, many cancer patients are left without access to potentially life-saving treatment.